Using lentiviral vectors for efficient pancreatic cancer gene therapy. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Cancer Gene Therapy Year : 2010

Using lentiviral vectors for efficient pancreatic cancer gene therapy.

Abstract

Pancreatic cancer (PC) remains a life-threatening disease. Efficient therapeutic gene delivery to PC-derived cells continues to present challenges. We used self-inactivated lentiviral vectors to transduce PC-derived cells in vitro and in vivo. We showed that lentiviral vectors transduce PC-derived cell lines with high efficiency (>90%), regardless of the differentiation state of the cell. Next, we transferred human interferon beta (hIFN-beta) gene. Expression of hIFN-beta in PC cells using lentiviral vectors resulted in the inhibition of cell proliferation and the induction of cell death by apoptosis. In vivo, lentiviral administration of hIFN-beta prevented PC tumor progression for up to 15 days following gene therapy, and induced tumor regression/stabilization in 50% of the mice treated. Again, hIFN-beta expression resulted in cancer cell proliferation inhibition and apoptosis induction. We provide evidence that human immunodeficiency virus (HIV)-1-based lentiviral vectors are very efficient for gene transfer in PC-derived cells in vitro and in vivo. As a consequence, delivery of hIFN-beta stopped PC tumor progression. Thus, our approach could be applied to the 85% of PC patients with a locally advanced disease.

Domains

Ethics
No file

Dates and versions

inserm-00480870 , version 1 (05-05-2010)

Identifiers

Cite

Emmanuel Ravet, Hubert Lulka, F. Gross, Louis Casteilla, Louis Buscail, et al.. Using lentiviral vectors for efficient pancreatic cancer gene therapy.. Cancer Gene Therapy, 2010, 17 (5), pp.315-24. ⟨10.1038/cgt.2009.79⟩. ⟨inserm-00480870⟩
72 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More